<DOC>
	<DOC>NCT01416194</DOC>
	<brief_summary>This observational cohort study is being conducted to further characterize selected adverse events of interest among a patient population with osteoporosis who are prescribed bazedoxifene, raloxifene, or a bisphosphonate in usual clinical care outside of a randomized clinical trial setting. The study will compare the rates of the selected clinical events among the three treatment groups.</brief_summary>
	<brief_title>Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)</brief_title>
	<detailed_description>All women in the database meeting the inclusion criteria will be included in the study without any statistical sampling.</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<mesh_term>Bazedoxifene</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<criteria>Female At least one prescription for bazedoxifene, raloxifene, or any bisphosphonate during the study inclusion period (index prescription); A recoded diagnosis code of osteoporosis on or within 60 days prior to the index prescription date; Age &gt;=45 at the date of the index prescription; and At least 6months of followup data in the electronic medical record system prior to the date of the index prescription There is no exclusion criteria. All women in the database who meet the inclusion criteria will be studied.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Osteoporosis</keyword>
</DOC>